Skip to main content
Top
Published in: Rheumatology International 4/2010

01-02-2010 | Short Communication

Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu’s arteritis

Authors: Tomohiro Koga, Yuichiro Nishino, Junya Makiyama, Takeshi Hayashida, Taichiro Miyashita, Yasumori Izumi, Mami Tamai, Atsushi Kawakami, Katsumi Eguchi, Kiysohi Migita

Published in: Rheumatology International | Issue 4/2010

Login to get access

Abstract

Takayasu’s arteritis (TA) is a rare large vessel vasculitis that is difficult to diagnose in the early stages. Therefore, it is also very difficult to manage and prevent irreversible vascular damage in TA. A 19-year-old female patient with back pain was examined using [18F]-FDG-PET to detect the source of inflammation. Specific accumulation of [18F]-FDG was observed in the thoracic and abdominal aorta, leading to the diagnosis of TA. Corticosteroid treatment resulted in clinical remission. However, the serum amyloid A (SAA) levels remained elevated. A follow-up scan showed residual uptake of [18F]-FDG in the thoracic aorta suggesting subclinical vascular inflammation. Methotrexate was combined with the corticosteroid, and the elevated levels of SAA became normalized. The present case suggests that monitoring serum levels of SAA and [18F]-FDG-PET could help clinicians to make adequate treatment adjustments in TA patients.
Literature
1.
2.
go back to reference Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G, Group ItakaStudy (2005) Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 53:100–107CrossRefPubMed Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G, Group ItakaStudy (2005) Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 53:100–107CrossRefPubMed
3.
go back to reference Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, Ishibashi-Ueda H, Kobayashi J, Yagihara T, Kitamura S (2008) Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 118:2738–2747CrossRefPubMed Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, Ishibashi-Ueda H, Kobayashi J, Yagihara T, Kitamura S (2008) Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 118:2738–2747CrossRefPubMed
4.
go back to reference Borg FA, Dasgupta B (2009) Treatment and outcomes of large vessel arteritis. Best Pract Res Clin Rheumatol 23:325–337CrossRefPubMed Borg FA, Dasgupta B (2009) Treatment and outcomes of large vessel arteritis. Best Pract Res Clin Rheumatol 23:325–337CrossRefPubMed
5.
go back to reference Andrews J, Mason JC (2007) Takayasu’s arteritis: recent advances in imaging offer promise. Rheumatology 46:6–15CrossRefPubMed Andrews J, Mason JC (2007) Takayasu’s arteritis: recent advances in imaging offer promise. Rheumatology 46:6–15CrossRefPubMed
6.
go back to reference Salvarani C, Cantini F, Boiardi L, Hunder GG (2003) Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 21:S23–S28PubMed Salvarani C, Cantini F, Boiardi L, Hunder GG (2003) Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 21:S23–S28PubMed
7.
go back to reference Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919–929PubMed Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919–929PubMed
8.
go back to reference Gabay C, Kushner I (1999) Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefPubMed Gabay C, Kushner I (1999) Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454CrossRefPubMed
9.
go back to reference Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B, Fitzgerald O (2000) Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 27:58–63PubMed Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B, Fitzgerald O (2000) Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 27:58–63PubMed
10.
go back to reference Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26:427–435CrossRefPubMed Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26:427–435CrossRefPubMed
11.
go back to reference Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford) 45(5):545–548CrossRef Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford) 45(5):545–548CrossRef
Metadata
Title
Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu’s arteritis
Authors
Tomohiro Koga
Yuichiro Nishino
Junya Makiyama
Takeshi Hayashida
Taichiro Miyashita
Yasumori Izumi
Mami Tamai
Atsushi Kawakami
Katsumi Eguchi
Kiysohi Migita
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1296-6

Other articles of this Issue 4/2010

Rheumatology International 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.